Table 1 Patients’ demographics

Number of Patients

111

62

Median Age (yr.) (Range)

60 (24–87)

65 (29–82)

Sex

 Male

59 (53)

43 (69)

 Female

52 (47)

19 (31)

Karnofsky Performance Status

 ≥70%

96 (86)

57 (92)

 <70%

15 (14)

4 (8)

Median BMI (range)

27 (16–47)

28 (15–46)

Osteoporosis

 Yes

9 (8)

1 (2)

 No

102 (92)

61 (98)

Steroid Use =/>4weeks

 Yes

12 (11)

6 (10)

 No

99 (89)

56 (90)

Bisphosphonate Use

 Yes

20 (18)

23 (37)

 No

91 (82)

39 (63)

Denosumab Use

 Yes

8 (7)

12 (19)

 No

103 (93)

50 (81)

Concurrent systemic therapy

 None

58 (52)

34 (55)

 Chemotherapy

19 (17)

11 (17)

 Immune therapy

15 (14)

11 (17)

 Targeted therapy

19 (17)

6 (11)

Median Prescription Dose (Gy) (Range)

27 (10–35)

27 (25–35)

Median Prescribed BED10 (Gy) (Range)

51.3 (20–60)

51.3 (37.5–60)

Median D80% (Gy)

27 (10.2–36)

28 (22.2–35.9)

Median D50% (Gy)

28 (10.3–38)

29 (24.1–37.8)

Isodose line

 >/=95%

74 (67)

40 (65)

 <95%

37 (33)

22 (35)

Median PTV (cc) (Range)

50 (8-465)

50 (6.3–348)

Median Conformity index (Range)

1.05 (0.42–1.4)

1 (0.7–1.16)

PTV coverage

 Partial vertebra

83 (75)

58 (94)

 Circumferential

28 (25)

4 (6)

Fractionation

 Single Fraction

22 (20)

0 (0)

 Multi Fraction

89 (80)

62 (100)

Number of Treated Spinal Levels

 1 level

64 (58%)

39 (63)

 2 levels

32 (29%)

13 (21)

 >2 levels

15 (13%)

10 (16)

Histopathology

 NSCLC/Breast/ano-colorectal

36 (32)

15 (34)

 Others

75 (68)

47 (66)

Spinal Instability Neoplastic Score Criteria

 < 7

73 (66)

32 (52)

 7

13 (11)

9 (14)

 >7

25 (23)

21 (34)

Bone lesion quality

 Blastic

38 (34)

13 (21)

 Mixed

24 (22)

21 (34)

 Lytic

49 (44)

28 (45)

Bilsky grade

 0

88 (79)

38 (61)

 1a

7 (6)

7 (11)

 1b

13 (12)

11 (18)

 1c

3 (3)

6 (9)

VCF

 Yes

20 (18)

10 (16)

 No

91 (82)

52 (84)

Median time to VCF (mo) (range)

5.2 (1.1–57.4)

3.6 (0.7–37.4)

EP-disrupted

 Yes

48 (43)

21 (34)

 No

63 (57)

41 (66)